A Study to Assess the Therapeutic  Effect of Enalapril on Olanzapine  Induced Metabolic Syndrome  in Wistar Rats

Arivazhahan, Avinash; Bairy, Laxminarayana Kurady; Nayak, Veena; Kunder, Sushil Kiran

doi:10.7860/jcdr/2017/24049.9380

Cited by 6 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of rodent studies have reported that chronic olanzapine treatment does not increase triglyceride and cholesterol plasma levels or induce weight gain independent increases in triglyceride levels. 2 , 3 , 8 , 33 Intriguingly, our results showed that the serum level of triglycerides was decreased in olanzapine but had no effect on total cholesterol. Considering that the liver and adipose tissue are the two main organs related to the physiopathology of metabolic dysfunction, the effects of olanzapine on target genes in the lipogenic and lipolytic pathways were investigated in adipose tissues and the liver.…”

Section: Discussionmentioning

confidence: 46%

Early Lipid Metabolic Effects of the Anti-Psychotic Drug Olanzapine on Weight Gain and the Associated Gene Expression

Chen¹,

Nakano²,

Hsu³

et al. 2022

NDT

View full text Add to dashboard Cite

Background Atypical antipsychotics such as olanzapine often cause metabolic side effects such as obesity and diabetes, leading to an increased risk of nonalcoholic fatty liver disease. The aim of the present study was to investigate the effects of olanzapine treatment on hepatic lipid metabolism and its possible relationship with adipose tissue status. Methods Using a female rat model, we investigated the effects of chronic olanzapine administration on the regulation of carbohydrate and lipid metabolism including lipid biosynthesis, oxidation, efflux, and lipolysis in liver and adipose tissue. Results The body weight, liver mass and visceral adiposity after olanzapine treatment (2 mg/kg) for five weeks were not significantly different compared with vehicle controls. The serum level of triglycerides was higher in the vehicle controls than in olanzapine-treated rats. Unexpectedly, olanzapine treatment did not reduce glucose tolerance in our model. The expression of functional thermogenic protein uncoupling protein 1 (UCP1) was increased in brown adipose tissue (BAT) of the olanzapine group. Additionally, olanzapine treatment also reduced adipose inflammation in white adipose tissue (WAT). The transcription factor sterol regulatory element-binding protein (SREBP)-1c, a key early regulator of lipogenesis, was downregulated following olanzapine treatment. The expression of genes related to the triglycerides synthesis apparatus in the liver was upregulated in the olanzapine group. Olanzapine treatment induced genes involved in PPAR-α signaling and mitochondrial fatty acid oxidation in response to increased ATGL-mediated lipolysis in the liver. Conclusion Together, our findings suggest a complicated link between olanzapine therapy and metabolic disturbance and may garner interest in assessing the action of antipsychotic-induced metabolic disturbances.

show abstract

Section: Discussionmentioning

confidence: 46%

Early Lipid Metabolic Effects of the Anti-Psychotic Drug Olanzapine on Weight Gain and the Associated Gene Expression

Chen¹,

Nakano²,

Hsu³

et al. 2022

NDT

View full text Add to dashboard Cite

show abstract

“…Metabolic syndrome is a cluster of cardiovascular diseases, and various risk factors such as an increase in blood pressure, insulin resistance, and blood coagulability cause an increase in obesity and neutral fat, and LDL-C, decreases in HDL-C, and the effect of dyslipidaemia (18). Olanzapine, an SGA, is used in the present study to induce metabolic syndrome at the dose of 2mg/kg (16). The study showed that with olanzapine treatment, there was a statistically significant (p<0.001) increase in body weight, total cholesterol, and triglycerides levels which is suggestive of metabolic syndrome.…”

Section: Discussionmentioning

confidence: 76%

“…The dose (2 mg/kg/day) and route (intraperitoneali.p.,) of olanzapine were chosen based on past investigations that indicated positive induction of MS in female Wistar rodents with this regimen (16). The probiotic dose was chosen by converting the adult human dose of a mean 70 kg man into a rat dose using the standard dose conversion formula.…”

Section: Selection Of Dose Of Medicationsmentioning

confidence: 99%

Effect of probiotics on olanzapine-induced metabolic syndrome in Wistar albino rats

Syed¹,

Nayak²

2023

Biomedicine

View full text Add to dashboard Cite

Introduction and Aim: Olanzapine is the most efficacious second-generation antipsychotic (SGA) used in the treatment of schizophrenia and at the same time, it is known to cause metabolic syndrome (MS). The aim was to assess the adequacy of probiotics in fighting the unfriendly impacts of olanzapine treatment such as weight gain, hyperlipidaemia, and hyperglycaemia in the olanzapine-induced MS model in rats. Materials and Methods: Thirty-six Wistar rats were divided into six groups (n=6), and were treated for 28 days as follows: Group-I: normal saline 1 ml/kg/day orally, Group-II: olanzapine 2 mg/kg/day i.p., Group-III: probiotic: 0.6 g/kg/day orally, Group-IV: probiotic: 1.2 g/kg/day orally, Group-V: olanzapine 2 mg/kg/day i.p., + probiotic: 0.6 g/kg/day orally, Group-VI: olanzapine 2 mg/kg/day i.p. + probiotic: 1.2 g/kg/day orally. Bodyweight, fasting blood glucose (FBG), and lipid profile were assessed at baseline and the end of each week. Data were analysed by applying repeated measures ANOVA, followed by a post-hoc Bonferroni test. P-value <0.05 was considered statistically significant. Results: There was a significant increment in the body weight, FBG, total cholesterol, and triglycerides level after olanzapine treatment (p<0.001), and similarly a decline in the body weight, FBG, total cholesterol, and triglycerides level in the probiotic-treated groups (p<0.001). There was a decrease in weight gain and FBG levels caused by olanzapine in the probiotic-treated groups. Conclusion: Probiotics forestalled the advancement of hyperlipidaemia, hyperglycaemia, decreased weight, and an increase in FBG levels induced by olanzapine. A long-term evaluation should also be directed to assess probiotics' impact on olanzapine-induced MS and their plausible mechanism.

show abstract

“…[29] Olanzapine is an SGA; it is used in the present study to induce metabolic syndrome at the dose of 2mg/kg. [27] The study showed that with olanzapine treatment, there was a statistically signi cant (p<0.001) increase in body weight, total cholesterol, and triglycerides levels which is suggestive of metabolic syndrome.…”

Section: Discussionmentioning

confidence: 92%

Effect of probiotics on olanzapine-induced metabolic syndrome in Wistar albino rats

Syed¹,

Nayak

2021

Preprint

View full text Add to dashboard Cite

Purpose: Olanzapine is the most viable second-generation antipsychotic (SGA) used in the treatment of schizophrenia and at the same time, it is the most notorious SGA to cause metabolic syndrome (MS). The target of this study is to assess the adequacy of probiotics in fighting the unfriendly impacts of olanzapine treatment such as weight gain, hyperlipidemia, and hyperglycemia in the olanzapine-induced MS model in rodents. Methods: Thirty-six Wistar rodents were haphazardly separated into six groups (n=6). The groups were treated for a month as follows: Group-I: Normal saline 1 ml/kg/day orally, Group-II: olanzapine 2 mg/kg/day i.p., Group-III: probiotic-VSL#3: 0.6 g/kg/day orally, Group-IV: VSL#3: 1.2 g/kg/day orally, Group-V: olanzapine 2 mg/kg/day i.p. + VSL#3: 0.6 g/kg/day orally, and Group-VI: olanzapine 2 mg/kg/day i.p. + VSL#3: 1.2 g/kg/day orally. Bodyweight, fasting blood glucose (FBG), and lipid profile was assessed at baseline and consequently at the end of each week. Data were analyzed by applying repeated measures ANOVA, followed by post-hoc Bonferroni test. P-value <0.05 was considered statistically significant. Results: There was a noteworthy increment in the total cholesterol and triglycerides level after olanzapine treatment (P<0.01), and similarly a decline in the total cholesterol and triglycerides level in the probiotic treated groups (p < 0.05). There was a decrease in weight increase and FBG levels instigated by olanzapine in the probiotic-treated groups. Conclusion: Probiotics forestalled the advancement of hyperlipidemia and decreased the weight addition and increment in FBG levels initiated by olanzapine. A long-haul evaluation should be directed to additionally assess the impact of probiotics on MS and their plausible mechanism.

show abstract

A Study to Assess the Therapeutic Effect of Enalapril on Olanzapine Induced Metabolic Syndrome in Wistar Rats

Cited by 6 publications

References 29 publications

Early Lipid Metabolic Effects of the Anti-Psychotic Drug Olanzapine on Weight Gain and the Associated Gene Expression

Early Lipid Metabolic Effects of the Anti-Psychotic Drug Olanzapine on Weight Gain and the Associated Gene Expression

Effect of probiotics on olanzapine-induced metabolic syndrome in Wistar albino rats

Effect of probiotics on olanzapine-induced metabolic syndrome in Wistar albino rats

Contact Info

Product

Resources

About